Other Solid Tumors Clinical Trials

31 clinical trials for Other Solid Tumors across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors — RECRUITING
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation — RECRUITING · PHASE1
• A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors — RECRUITING · PHASE1
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions — RECRUITING · PHASE1
• Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors — RECRUITING · PHASE1
• Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors — RECRUITING · PHASE1
• Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) — TERMINATED · PHASE1
• A Study of SGN-MesoC2 in Advanced Solid Tumors — TERMINATED · PHASE1
• A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors — TERMINATED · PHASE1
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors — NOT_YET_RECRUITING · PHASE1
• A Study of CDX-585 in Patients With Advanced Malignancies — COMPLETED · PHASE1
• A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China — COMPLETED · PHASE1
• Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment — COMPLETED · PHASE1
• A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors — COMPLETED · PHASE2
• CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers — NOT_YET_RECRUITING · PHASE1
• A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies — COMPLETED · PHASE1
• A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) — TERMINATED · PHASE1
• A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) — COMPLETED · PHASE1
• KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors — OTHER · PHASE1
• A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies — COMPLETED · PHASE1
• Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations — TERMINATED · PHASE1
• A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor — OTHER · PHASE1
• Phase I/II Study of PDR001 in Patients With Advanced Malignancies — COMPLETED · PHASE1
• A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors — COMPLETED · PHASE1
• Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors — TERMINATED · PHASE1
• A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. — TERMINATED · PHASE1
• A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) — COMPLETED · PHASE1
• Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors — TERMINATED · PHASE1

Refine this search